Health News Releases

  • Today April 9
September 27, 2019 10:47
New Data Presented at World Sleep Congress Demonstrate Early Signs of Efficacy for TAK-925, a Selective Orexin Type-2 Receptor (OX2R) Agonist, in Patients with Narcolepsy Type 1
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) announced results of a Phase 1 clinical proof of concept study of the novel investigational compound TAK-925, a selective orexin ty
September 26, 2019 11:13
First Head-to-Head Biologic Study in Ulcerative Colitis Published in The New England Journal of Medicine Highlights Benefit of Vedolizumab vs. Adalimumab
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the VARSITY study, which demonstrated the superiority of the gut-selective biologic vedolizuma
September 25, 2019 09:12
New England Journal of Medicine Publishes Results of a Phase 2 Trial Evaluating Takeda’s TAK-620 (Maribavir) as a Potential Treatment of Cytomegalovirus (CMV) Infection
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the New England Journal of Medicine has published results of a Phase 2, randomised, 12-week, open-label study
September 24, 2019 10:28
Study Investigates the Ability of Masimo Noninvasive, Continuous Hemoglobin (SpHb®) to Provide Earlier Indication of Anemia and the Impact of Anemia on Patient Outcomes
Masimo (NASDAQ: MASI) announced today that in a study published in Injury, researchers used Masimo SpHb® - noninvasive, continuous hemoglobin monitoring - to investigate possible delays in the detecti
September 23, 2019 16:09
Patient Safety Leaders and Advocates Discuss Solutions to Eliminate Preventable Patient Deaths
On the same day the World Health Organization (WHO) designated World Patient Safety Day, The Patient Safety Movement Foundation’s (PSMF) Midyear Planning Meeting (MYPM) brought together more than a hu
September 23, 2019 14:08
Takeda Recognized in the 2019 Dow Jones Sustainability World Index
Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502/NYSE:TAK) today announced that it has been named in the 2019 Dow Jones Sustainability World Index, achieving more than double the average o
September 23, 2019 13:56
Larger, healthier, more plentiful — Study proves House Wellness Foods’ Feed LP20® improves stock at the cellular level.
Eons ago, the progress of humankind was thrust forward with the development of farming. Today that progress is challenged simultaneously by climatic and socioeconomic forces, and the future hangs in t
September 23, 2019 13:10
Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases
Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies for patients with
September 20, 2019 13:55
Taiwan: Rising Importance of Proton Therapy and a Fortress for Cancer Treatment
There is no place like Taiwan where medical services are readily accessible with quality and efficiency, attracting nearly 500,000 patients worldwide annually and attention from dominant medical devic
September 20, 2019 11:15
Solasia Announces Patient Registration Reached Target Number of Cases for Darinaparsin Phase 2 Pivotal Study for T-Cell Lymphoma
Solasia Pharma K.K. (TSE:4597, Headquarters: Tokyo, President & CEO: Yoshihiro Arai, hereinafter “Solasia”), a specialty pharmaceutical company based in Asia, today announced that patient registration
September 20, 2019 09:05
Consistent cardiovascular benefits shown with empagliflozin treatment regardless of the number of controlled cardiovascular risk factors
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced results of a post-hoc analysis of the landmark EMPA-REG OUTCOME® trial that were presented at the 55th Annual Meeting of the
September 19, 2019 10:23
Three Hospital Systems Earn Five-Star Award from Patient Safety Movement Foundation
On the first World Patient Safety Day, the Patient Safety Movement Foundation (PSMF) announces that it has awarded Dignity Health, MedStar Health and the UPMC with its five-star award for making commi
September 16, 2019 13:50
Hansoh Pharma and Atomwise Launch Strategic AI Drug Discovery Collaboration for Multiple Therapeutic Areas
Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”), a leading biopharmaceutical company in China, and Atomwise, Inc. (“Atomwise”), the leader in artificial intelligence (AI) for drug discov
September 16, 2019 09:26
Aptorum Group Has Initiated IND-Enabling Studies For Its ALS-4 Small Molecule Candidate For The Treatment Of Infections Caused By Staphylococcus Aureus Including MRSA
Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces that it has initiat
September 16, 2019 09:19
Aptorum Group Announces the Development of Microbiome Drug Candidate Targeting Obesity and Repurposed Drug Candidates Targeting Neuroblastoma
Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces the development of
September 10, 2019 09:04
Data from Ozanimod Clinical Development Program in Relapsing Forms of Multiple Sclerosis to Be Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Celgene Corporation (NASDAQ:CELG) today announced it will present 13 scientific abstracts, including new analyses from the Phase 3 ozanimod clinical development program in adults with relapsing forms
September 09, 2019 11:03
Walgreens Boots Alliance Appoints Global Chief Information Officer
Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced Francesco Tinto was named global chief information officer (CIO) and senior vice president at the company, which ranks #17 on the Fortune 5
September 05, 2019 17:00
After Successful Technical Feasibility the Swiss Company SAV-IOL is Now Seeking Investors for Smart Active Intraocular Lens Project for Cataract Surgery
SAV-IOL (Swiss Advanced Vision) is moving forward with the development of the R-TASC Project, the first electronic intraocular lens (IOL) with real-time autofocus, aimed to fully restore the vision po
September 05, 2019 10:12
GVK BIO Announces the Promotion of Sudhir Kumar Singh to Chief Operating Officer and Appointment of Ramesh Subramanian as the New Chief Commercial Officer of GVK BIO
GVK BIO, a leading global Contract Research and Development Organisation (CRDO), is pleased to announce the promotion of Sudhir Kumar Singh, Ph.D., to the position of Chief Operating Officer and the a
September 04, 2019 17:43
Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound
Boehringer Ingelheim and Lupin Limited (Lupin) today announced a licensing, development and commercialization agreement for Lupin’s MEK inhibitor compound (LNP3794) as a potential targeted therapy for
September 04, 2019 17:40
Results from RE-SPECT CVT® published - first trial of NOAC in cerebral venous thrombosis
Boehringer Ingelheim today announced the publication of primary analysis from RE-SPECT CVT®, the first exploratory, prospective, randomised controlled study of a NOAC in patients with blood clots in t
September 04, 2019 11:12
GN Hearing Becomes World’s First to Support Direct Android Streaming to Hearing Devices Using Bluetooth Low Energy
GN Hearing, the global leader in hearing aid connectivity, and Cochlear, the global leader in implantable hearing solutions, together with Google, today announce world-first support for direct streami
September 03, 2019 17:10
Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes
Boehringer Ingelheim and Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL), have announced that Boehringer Ingelheim plans to initiate Phase 2 development of the GLP-1/glucagon dual agonist BI 456906, whi
September 02, 2019 10:47
Concept Medical Inc. Granted ‘Breakthrough Device Designation’ From the FDA for Its MagicTouch AVF Sirolimus Coated Balloon
Concept Medical Inc. (CMI) has been granted “Breakthrough Device Designation” from the U.S. Food and Drug Administration (FDA) for MagicTouch AVF, its Sirolimus drug-coated balloon (DCB) catheter, for
August 30, 2019 17:20
Anniversary of the pivotal RE-LY® trial marks a decade of innovation for stroke prevention in AF patients
Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication[1-3] recognising the contribution made in the decade since by patients, healthcare professionals (HCPs) an
25 per page50 per page75 per page100 per page